Astellas Pharma Inc. - Net Income Applicable To Common Shares

Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Net-Income-Applicable-To-Common-Shares" stands at 124.87 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2022.

Astellas Pharma Inc.'s second quarter result of 79.21 Billion JPY for the item "Net Income Applicable To Common Shares" represents an increase of 15.77 percent compared to it's first quarter result.

Also, Astellas Pharma Inc.'s second quarter result of 79.21 Billion JPY for the item "Net Income Applicable To Common Shares" represents an increase of 120.60 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s second quarter result of 124.87 Billion JPY for the item "Net Income Applicable To Common Shares" represents an increase of 53.09 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 70.12 Billion Japanese Yens compared to the value the year prior.
The 1 year change is 70.12 Billion Japanese Yens.
The 3 year change is -0.634 Billion Japanese Yens.
The 5 year change is -14.85 Billion Japanese Yens.
The 10 year change is -43.93 Billion Japanese Yens.

The Serie's long term average value is 127.11 Billion Japanese Yens. It's latest available value, on 09/30/2025, is -2.23 Billion Japanese Yens lower, compared to it's long term average value.
The Serie's change in Japanese Yens from it's minimum value, on 12/31/2024, to it's latest available value, on 09/30/2025, is +182.30 Billion.
The Serie's change in Japanese Yens from it's maximum value, on 09/30/2019, to it's latest available value, on 09/30/2025, is -122.06 Billion.